OPK - ModeX Therapeutics secures BARDA contract to develop novel multispecific antibodies

2023-09-29 04:41:48 ET

• ModeX Therapeutics, an OPKO Health ( NASDAQ: OPK ) company, has been awarded a contract from the Biomedical Advanced Research and Development Authority, to advance a platform and specific candidates designed to address a range of public health threats in viral infectious diseases.
• The awarded funding will enable research, development and clinical evaluation of potent multispecific antibodies, based on ModeX proprietary MSTAR technology.
• This initiative builds on a collaboration between ModeX and the Vaccine Research Center of the National Institutes of Health for the discovery and characterization of novel therapeutic antibodies against SARS-CoV-2.
• OPK +10.67% premarket to $1.66.
• Source: Press Release

For further details see: